These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35094254)

  • 21. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Khan KJ; Ullman TA; Ford AC; Abreu MT; Abadir A; Marshall JK; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):661-73. PubMed ID: 21407187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting.
    Bokemeyer B; Ghiani M; Fuchs A; Deiters B; Hardtstock F; Brandes A; Knop J; Orzechowski HD; Wilke T
    Int J Colorectal Dis; 2020 Aug; 35(8):1587-1598. PubMed ID: 32424526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.
    Yang C; Singh P; Singh H; Le ML; El-Matary W
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1079-93. PubMed ID: 25858208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies.
    Bahnam P; Hanzel J; Ma C; Zou L; Narula N; Singh S; Kahan B; Jairath V
    J Crohns Colitis; 2023 Apr; 17(3):404-417. PubMed ID: 36219564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis.
    Barberio B; Gracie DJ; Black CJ; Ford AC
    Dig Liver Dis; 2024 Jan; 56(1):7-14. PubMed ID: 37357037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.
    Fang S; Zhang S; Zhang C; Wang L
    Paediatr Drugs; 2023 Sep; 25(5):499-513. PubMed ID: 37528211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
    Kotze PG; Ma C; Almutairdi A; Al-Darmaki A; Devlin SM; Kaplan GG; Seow CH; Novak KL; Lu C; Ferraz JGP; Stewart MJ; Buresi M; Jijon H; Mathivanan M; Heatherington J; Martin ML; Panaccione R
    Aliment Pharmacol Ther; 2018 Sep; 48(6):626-637. PubMed ID: 30063077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
    Seishima R; Okabayashi K; Ikeuchi H; Uchino M; Futami K; Noguchi T; Ohge H; Iseki Y; Watanabe K; Itabashi M; Okamoto K; Toiyama Y; Ogino T; Nakamura M; Yamada K; Wakai T; Sato Y; Kimura H; Takahashi K; Hida K; Kinugasa Y; Ishida F; Okuda J; Daito K; Koyama F; Ueno H; Yamamoto T; Yamamoto S; Hanai T; Maemoto A; Arakaki J; Komori K; Akagi Y; Shida D; Yamaguchi S; Matsuda K; Maeda K; Noake T; Nezu R; Sasaki S; Hasegawa J; Sunami E; Kanemitsu Y; Katsumata K; Uehara K; Kiyomatsu T; Suto T; Kazama S; Yamada T; Goi T; Ishihara S; Ajioka Y; Sugihara K
    Am J Gastroenterol; 2023 Jul; 118(7):1248-1255. PubMed ID: 36622356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
    Mao EJ; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 Jan; 45(1):3-13. PubMed ID: 27862107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials.
    Ben-Horin S; Zhao Y; Guo J; Mao R; Novack L; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Colombel JF; Peyrin-Biroulet L; Kaplan G; Chen MH
    BMJ Open; 2019 Jan; 9(1):e024222. PubMed ID: 30782731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDO
    di Giuseppe R; Plachta-Danielzik S; Mohl W; Hoffstadt M; Krause T; Bokemeyer B; Schreiber S
    Int J Colorectal Dis; 2021 Nov; 36(11):2445-2453. PubMed ID: 33963913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease.
    Wils P; Jairath V; Sands BE; Magro F; Reinisch W; Rubin D; Danese S; Baumann C; Peyrin-Biroulet L
    United European Gastroenterol J; 2023 Oct; 11(8):797-806. PubMed ID: 37670487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
    Zhao M; Lirhus S; Lördal M; Langholz E; Knudsen T; Voutilainen M; Høivik ML; Moum B; Anisdahl K; Saebø B; Haiko P; Malmgren C; Coskun M; Melberg HO; Burisch J
    Aliment Pharmacol Ther; 2022 Sep; 56(6):989-1006. PubMed ID: 35902223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials.
    Shen J; Zuo ZX; Mao AP
    Inflamm Bowel Dis; 2014 Jan; 20(1):21-35. PubMed ID: 24280877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
    Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
    J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.